Interim FDG‐PET does not predict outcome in advanced‐stage Hodgkin lymphoma patients treated with BEACOPP

Adams, Hugo J. A.; Kwee, Thomas C.

doi:10.1111/bjh.15602

Cited by 3 publications

(2 citation statements)

References 10 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We must note that in current practice Deauville 5 score indicates the need for treatment intensification in patients treated by ABVD, although there are no outcome differences in patients initially treated with BEACOPPesc. 9,10 Responses were assessed according to Cheson criteria for malignant lymphoma from 2007. 11 Primary endpoint of the study was modified PFS (mPFS).…”

Section: Methodsmentioning

confidence: 99%

“…It was important to note that interim Deauville 5 score was not counted as an event in the absence of CT and PET new lesion. We must note that in current practice Deauville 5 score indicates the need for treatment intensification in patients treated by ABVD, although there are no outcome differences in patients initially treated with BEACOPPesc . Responses were assessed according to Cheson criteria for malignant lymphoma from 2007…”

Section: What Have We Learned From Echelon‐1?mentioning

confidence: 99%

See 1 more Smart Citation

FDA's and EMA's approval of brentuximab vedotin for advanced Hodgkin lymphoma: Another player in the town?

Milunović

Jakobac

Kursar

et al. 2019

European J of Haematology

View full text Add to dashboard Cite

ECHELON-1 study is a randomized open-labeled controlled trial investigating whether addition of brentuximab vedotin to chemotherapy offers benefit over the standard chemotherapy regimen in advanced Hodgkin lymphoma. After a median follow-up of 24.6 months, it has met its primary endpoint the reduction of modified progression-free survival being 23 percent. However, the beneficial effects have not been seen across all subgroups leading to further questions. The main aim of this review is to tackle these questions to provide the reader with in-depth insight of pros and cons of this novel, promising but ultimately controversial regimen. K E Y W O R D Sbrentuximab vedotin, Hodgkin lymphoma, induction chemotherapy, monoclonal antibodies

show abstract

Section: Methodsmentioning

confidence: 99%

Section: What Have We Learned From Echelon‐1?mentioning

confidence: 99%